Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on ...
Biotechnology company Moderna (NASDAQ:MRNA) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 45.4% ...
Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...
Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...
Investing.com - Moderna (NASDAQ: MRNA) reported third quarter EPS of $-0.51, $1.54 better than the analyst estimate of $-2.05. Revenue for the quarter came in at $1.02B versus the consensus estimate ...
Moderna posts a smaller Q3 loss, trims 2025 sales forecast, cuts R&D costs, and boosts cash outlook as COVID vaccine demand ...
Mixed earnings results were being mentioned on Thursday as possible catalysts behind Thursday's stock-market action. Shares of Moderna Inc. were up more than 3% after the vaccine maker reported a ...
Qualcomm (NASDAQ:QCOM) stock dropped 1.4% as fears the chip designer will lose business from Samsung, a key customer, ...
Zacks.com on MSN
Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates
Moderna (MRNA) delivered earnings and revenue surprises of +76.28% and +18.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Moderna Inc. continues to push its cost-savings work as Covid-19 vaccination rates decline. The company's third-quarter 2025 ...
Moderna beats Q3 forecasts as cost-cutting offsets weaker COVID vaccine sales and new mRNA cancer trials advance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback